Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± Ipilimumab vs Pemetrexed + Platinum in EGFR-mutant NSCLC after EGFR TKI Failure
CTR20170541Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170541.